RELEASE DATE: June 10, 2019
EXPIRATION DATE: June 10, 2020
LDL-C is a central focus of cardiovascular risk reduction. Prudent use of PCSK9 inhibitors requires identifying patients with elevated LDL-C at increased risk. High-risk patients include ASCVD patients and those with LDL-C > 190 mg/dL without ASCVD. Awareness of evidence with PCSK9 inhibitors, discussions of best use of PCSK9 inhibitors by lipid experts, and cases aim to facilitate treatment of appropriate patients with these drugs to optimize outcomes. In this program, Chair Dr. James Underberg, and Drs. Ty Gluckman, Margo Minissian, Michael Shapiro, and Pam Taub will use these formats to assist lipidologists in patient management with PCSK9 inhibitors.
Enduring Internet Activity
This activity is designed to meet the needs of lipidologists, internists, endocrinologists, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses and registered dietitians with an interest in lipid management.
At the Conclusion of this activity, participants should be able to:
- Recognize that LDL‐C remains a central focus of cardiovascular risk reduction.
- Discuss key principles of cholesterol management and the role of statin therapy.
- Identify patients for consideration for PCSK9 inhibitor therapy.
- Describe increased risks associated with ASCVD patients and patients with LDL‐C > 190 mg/dL with or without Familial Hypercholesterolemia.
- Interpret evidence with PCSK9 inhibitors in patients with ASCVD and severe hypercholesterolemia.
- Discuss strategies to improve the knowledge, skills or performance of the healthcare team.
CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s participation in the activity and post-assessment with a score of 75% or greater and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme. The deadline to claim credit is June 10, 2020.
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.
This activity is supported by an educational grant from Amgen.
CME credit provided by the National Lipid Association
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association and VoxMedia. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation Statement
The National Lipid Association designates this enduring internet activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.
Pharmacist Accreditation Statement
Universal Activity Number – JA0007192-9999-19-018-H01-P (Knowledge)
This Activity has been approved for 2 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education.
The maximum number of hours awarded for this CE activity is 2.0 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
James A. Underberg, MD, MS
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
President, National Lipid Association
New York, NY
Medical Director, Center for Cardiovascular
Analytics, Research, and Data Science
Providence St. Joseph Heart Institute
Cardiology Nurse Practitioner
Clinical Lipid Specialist
Barbra Streisand Women’s Heart Center
Cedars-Sinai Heart Institute
Los Angeles, CA
Associate Professor of Medicine and Radiology
Oregon Health & Science University
Associate Professor of Medicine
University of California San Diego
La Jolla, CA
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.
|Gluckman, Ty||Other (Expert Witness)||AbbVie/Teva|
|Shapiro, Michael||Advisory Board||Esperion|
|Taub, Pam||Consultant||Amgen, Boehringer Ingelheim, Janssen, Novo Nordisk, Pfizer, Sanofi/ Regeneron|
|Speaker||Amgen, Boehringer Ingelheim, Janssen, Novo Nordisk, Sanofi/Regeneron|
|Underberg, James||Advisory Board||Akcea, Alexion, Ambry, Amgen, Invitae, Regeneron, Sanofi|
|Contracted Research||Aegerion, Pfizer, Sanofi|
|Speaker||Alexion, Amarin, Amgen, Regeneron, Sanofi|
|Steering Committee||Aegerion LOWER Registry Trial|
|NLA||N/A||NLA staff has nothing to disclose.|
|Voxmedia LLC||N/A||Voxmedia LLC staff has nothing to disclose.|
|Gupta, Eric||N/A||Has nothing to disclose.|
This page was last updated: Jun 06, 2019